NCT06749210 DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
| NCT ID | NCT06749210 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Ohio State University Comprehensive Cancer Center |
| Condition | Cancer of the Breast |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-02-19 |
| Primary Completion | 2029-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 140 participants in total. It began in 2025-02-19 with a primary completion date of 2029-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Eligibility Criteria
Inclusion Criteria: * Breast Cancer (BC) diagnosis of Stage I-IV including metastatic disease * completed taxane-based chemotherapy for BC at least 3 months ago (no limit on how long ago) * symptomatic for chemotherapy-induced neuropathy (self-report) * postural control score that indicates potential fall-risk * able to understand and comply with directions associated with testing and study treatments Exclusion Criteria: * pre-existing vestibular dysfunction * poorly controlled diabetes (hgA1C\>=8) * non-ambulatory (assistive and prosthetic devices allowed) * hearing impairment resulting in less than 10% hearing bilaterally * contraindication to participate in the experimental physical activity per the treating oncologist due to additional condition (e.g., herniated disc, unstable bone metastases) * currently in activity-based therapy (e.g., physical therapy, occupational therapy). May enroll if still meet eligibility criteria once activity-based therapy is complete.
Contact & Investigator
Lise B Worthen-Chaudhari, PhD, MFA, CMES
PRINCIPAL INVESTIGATOR
Ohio State University
Frequently Asked Questions
Who can join the NCT06749210 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Cancer of the Breast. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06749210 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06749210 currently recruiting?
Yes, NCT06749210 is actively recruiting participants. Contact the research team at lise.worthen-chaudhari@osumc.edu for enrollment information.
Where is the NCT06749210 trial being conducted?
This trial is being conducted at New Haven, United States, Columbus, United States.
Who is sponsoring the NCT06749210 clinical trial?
NCT06749210 is sponsored by Ohio State University Comprehensive Cancer Center. The principal investigator is Lise B Worthen-Chaudhari, PhD, MFA, CMES at Ohio State University. The trial plans to enroll 140 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.